TWST
$47.14+2.13 (+4.73%)
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...
Recent News
Assessing Twist Bioscience (TWST) Valuation After Insider Sale And Recent Q1 FY26 Optimism
Twist Bioscience (TWST) stock came under pressure after Senior Vice President of Human Resources Paula Green sold more than 39,400 shares for nearly US$2.1 million, following a strong year to date rally. See our latest analysis for Twist Bioscience. The recent insider sale comes after a strong year to date share price return of 53.07% and a 56.40% 3 month share price return, alongside the Invenra licensing agreement and upbeat Q1 FY26 guidance. At the same time, the 1 year total shareholder...
Twist Bioscience Adds Invenra Bispecific Platform To Broaden Discovery Opportunity
Twist Bioscience (NasdaqGS:TWST) entered a licensing agreement with Invenra Inc. to co-exclusively provide Invenra's B-Body bispecific antibody platform. The deal broadens Twist's antibody discovery offerings across in vivo, in vitro, and AI-enabled workflows. Twist also gains a direct ownership stake in Invenra and potential future revenue participation from bispecific discovery services and licensing. For you as an investor, this move adds another building block to Twist Bioscience's role...
Biotech Beat Nvidia in 2025. Can It Do It Again?
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
Twist Bioscience Annual Meeting: Shareholders Elect Directors, Approve Pay and EY Auditor Ratification
Twist Bioscience (NASDAQ:TWST) held its 2026 annual meeting of stockholders via an online webcast, with Lead Independent Director Robert Chess serving as chairman. The meeting focused on three standard items of corporate governance: electing directors, conducting a non-binding advisory vote on execu
Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
Twist Bioscience (NasdaqGS:TWST) raised its full year revenue guidance, reflecting updated expectations for its business in synthetic DNA and protein solutions. The company highlighted strong demand for its AI enabled DNA and protein platforms, supported by expanding collaborations across discovery and research. Twist Bioscience also announced significant inducement equity awards tied to recent hires, aimed at supporting ongoing growth initiatives. Twist Bioscience, trading at $48.12, has...